Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

NCT ID: NCT00507416

Last Updated: 2014-05-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 502 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2013-03-31

Brief Summary

This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.

Conditions

Multiple Myeloma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Bortezomib and Dexamethasone (VD)

Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).

Group Type: EXPERIMENTAL

Bortezomib

Intervention Type: DRUG

Bortezomib bolus intravenous (IV) injection

Dexamethasone

Intervention Type: DRUG

Dexamethasone for oral administration

Bortezomib, Thalidomide, and Dexamethasone (VTD)

Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .

Group Type: EXPERIMENTAL

Bortezomib

Intervention Type: DRUG

Bortezomib bolus intravenous (IV) injection

Dexamethasone

Intervention Type: DRUG

Dexamethasone for oral administration

Thalidomide

Intervention Type: DRUG

Thalidomide for oral administration

Bortezomib, Melphalan and Prednisone (VMP)

Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).

Group Type: EXPERIMENTAL

Bortezomib

Intervention Type: DRUG

Bortezomib bolus intravenous (IV) injection

Melphalan

Intervention Type: DRUG

Melphalan for oral administration

Prednisone

Intervention Type: DRUG

Prednisone for oral administration

Interventions

Bortezomib

Bortezomib bolus intravenous (IV) injection

Intervention Type: DRUG

Dexamethasone

Dexamethasone for oral administration

Intervention Type: DRUG

Melphalan

Melphalan for oral administration

Intervention Type: DRUG

Prednisone

Prednisone for oral administration

Intervention Type: DRUG

Thalidomide

Thalidomide for oral administration

Intervention Type: DRUG

Other Intervention Names

Velcade

Eligibility Criteria

Inclusion Criteria

• Male or female 18 years of age or older
• Not a candidate for high-dose chemotherapy and stem cell transplantation (HDT/SCT) due to age, presence of important comorbid condition(s) likely to have a negative impact on tolerability of HDT-SCT, or subject preference.
• A Karnofsky Performance Status score of ≥50%
• Symptomatic multiple myeloma or asymptomatic multiple myeloma with related organ or tissue damage.
• Asymptomatic multiple myeloma-related organ or tissue damage can include presence of an asymptomatic lytic bone lesion or plasmacytoma, the presence of anemia (hemoglobin <10 g/dL), renal function impairment (serum creatinine > upper limit of normal [ULN]) or hypercalcemia (serum calcium >ULN).
• Must have measurable disease requiring systemic therapy. Measurable disease is defined by at least 1 of the following criteria:

• Quantifiable serum M-protein value (>1 g/dL of immunoglobulin (Ig)G or IgM M-protein, >0.5g/dL of IgA M-protein, >0.5 g/dL of IgD M-protein)
• Urine light-chain excretion ≥200 mg/24 hours
• Voluntary written informed consent must be given before performance of any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Exclusion Criteria

• Diagnosis of smoldering multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS). Smoldering multiple myeloma is defined as asymptomatic multiple myeloma with absence of lytic bone lesions. MGUS is defined by presence of serum monoclonal protein <3 g/dL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the monoclonal protein; and (if determined) proportion of plasma cells in the bone marrow of 10% or less.
• Diagnosis of Waldenström's disease or other conditions in which immunoglobulin M (IgM) M-protein is present in the absence of a clonal plasma cell infiltration or lytic bone lesions.
• Previously or currently treated with any systemic therapy for multiple myeloma. Prior treatment of hypercalcemia or spinal cord compression with corticosteroids or radiation therapy, respectively, does not disqualify the subject (the dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone in 2-week period).
• Radiation therapy within 2 weeks before randomization. Enrollment of patients who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 2 weeks have elapsed since the last date of therapy.
• Major surgery within 30 days before randomization (Kyphoplasty is not considered major surgery)
• History of allergy to any of the study medications, their analogues, or excipients in the various formulations
• ≥Grade 2 peripheral neuropathy on clinical examination within 21 days before enrollment.
• Any of the following clinical laboratory values within 21 days prior to enrollment:

• Absolute neutrophil count (ANC) <1000 cells/mm^3
• Platelets <100,000 × 10^9/L, or <70 × 10^9/L if thrombocytopenia is considered by the investigator to be due to myeloma infiltration of bone marrow
• Aspartate aminotransferase [serum glutamic oxaloacetic transaminase] (AST [SGOT]) or alanine aminotransferase [serum glutamic-pyruvic transaminase] (ALT [SGPT]) >2× the upper limit of normal (ULN)
• Serum creatinine >2 mg/dL (>176.8 µmol/L); if the rise in creatinine is related to myeloma and there has been demonstrated a response to hydration, the subject may be enrolled.
• Myocardial infarction within 6 months prior to enrollment or New York Hospital Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or significant conduction system abnormalities in the opinion of the investigator. Prior to study entry, any abnormality on electrocardiogram at screening must be determined and documented by the investigator as not medically relevant.
• Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the patient at unacceptable risk if he/she were to participate in the study. This includes but is not limited to serious medical conditions or psychiatric illness likely to interfere with participation in this clinical study.
• Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer, or other cancer for which the patient has been disease-free for at least 3 years.
• Female who is pregnant or breastfeeding. Female participants of childbearing potential must have a negative pregnancy test with a sensitivity of at least 50 mIU/mL during Screening.
• Use of any investigational drugs within 30 days before randomization.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Millennium Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Millennium Pharmaceuticals, Inc.

Locations

Birmingham Hematology Oncology Assciates, LLC

Birmingham, Alabama, United States

Desert Oasis Cancer Center

Casa Grande, Arizona, United States

Northern Arizona Hematology & Oncology Associates - AOA

Sedona, Arizona, United States

Arizona Oncology Associates

Tucson, Arizona, United States

Heritage Physician Group Oncology

Hot Springs, Arkansas, United States

Hematology Oncology Services of Arkansas

Little Rock, Arkansas, United States

Pacific Cancer Medical Centre

Anaheim, California, United States

Tower Cancer Research Foundation

Beverly Hills, California, United States

Compassionate Cancer Care Medical Group

Corona, California, United States

Compassionate Cancer Care Medical Group, Inc.

Fountain Valley, California, United States

Robert A. Moss, MD, FACP, Inc.

Fountain Valley, California, United States

Cancer Care Associates

Fresno, California, United States

Glendale Memorial Hospital & Health Center

Glendale, California, United States

California Cancer Care

Greenbrae, California, United States

Beaver Medical Group

Highland, California, United States

Edward A. Wagner, MD

Laguna Beach, California, United States

Clinical Trials and Research Associates, Inc.

Montebello, California, United States

Medical Oncology Care Associates

Orange, California, United States

Ventura County Hematology Oncology Specialists

Oxnard, California, United States

Southwest Cancer Care

Poway, California, United States

Desert Cancer Care, Incorporated

Rancho Mirage, California, United States

Compassionate Cancer Care Medical Group, Inc.

Riverside, California, United States

Sutter Cancer Center

Sacramento, California, United States

Cancer Research & Prevention Center

Soquel, California, United States

Stockton Hematology/Oncology

Stockton, California, United States

Trivalley Oncology Hematology

Westlake Village, California, United States

Rocky Mountain Cancer Center

Denver, Colorado, United States

Cancer Center of Central Connecticut

Southington, Connecticut, United States

Christiana Care Health Services

Newark, Delaware, United States

The Center for Hematology-Oncology

Boca Raton, Florida, United States

Pasco Hernando Oncology

Brooksville, Florida, United States

Northwest Oncology & Hematology Associates

Coral Springs, Florida, United States

Florida Cancer Specialists

Fort Myers, Florida, United States

Horizon Institute for Clinical Research

Hollywood, Florida, United States

Baptist Cancer Institute

Jacksonville, Florida, United States

University of Florida- Jacksonville

Jacksonville, Florida, United States

Cancer Care of North Florida

Lake City, Florida, United States

Lakeland Regional Cancer Center

Lakeland, Florida, United States

Cancer & Blood Disease Center

Lecanto, Florida, United States

Pasco Hernando Oncology

New Port Richey, Florida, United States

Florida Cancer Institute

New Port Richey, Florida, United States

Innovative Medical Research of South Florida Inc.

North Miami Beach, Florida, United States

Ocala Oncology Center

Ocala, Florida, United States

Cancer Centers of Florida, P.A.

Ocoee, Florida, United States

MD Anderson Cancer Center Orlando

Orlando, Florida, United States

Hematology Oncology Associates of the Treasure Coast, PA

Port Saint Lucie, Florida, United States

Gulfcoast Oncology Associates

St. Petersburg, Florida, United States

S. Florida Oncology/ Hematology

West Palm Beach, Florida, United States

Medical Oncology Associates of Augusta

Augusta, Georgia, United States

Central Georgia Cancer Care

Macon, Georgia, United States

Northwest Georgia Oncology Centers, P.C.

Marietta, Georgia, United States

Summit Cancer Care

Savannah, Georgia, United States

St. Lukes Mountain States Tumor Institute

Boise, Idaho, United States

Snake River Oncology of Eastern Idaho, PLLC.

Idaho Falls, Idaho, United States

Cancer Care & Hematology Specialists of Chicagoland

Arlington Heights, Illinois, United States

Hematology Oncology Associates of Illinois

Chicago, Illinois, United States

John H. Stroger, Jr. Hospital of Cook County

Chicago, Illinois, United States

University of Chicago

Chicago, Illinois, United States

Hematology Oncology Associates of Illinois

Chicago, Illinois, United States

Elmhurst Memorial Hospital

Elmhurst, Illinois, United States

Oncology Hematology Associates of North Illinois Ltd.

Gurnee, Illinois, United States

Midwest Center for Hematology / Oncology

Joliet, Illinois, United States

Joliet Oncology-Hematology Associates, Ltd.

Joliet, Illinois, United States

Hematology Oncology Consultants, Inc.

Naperville, Illinois, United States

Cancer Care and Hematology Specialists of Chicagoland

Niles, Illinois, United States

Mid-Illinois Hem & Onc

Normal, Illinois, United States

Quincy Medical Group

Quincy, Illinois, United States

Deaconess Clinic Incorporated

Evansville, Indiana, United States

Central Indiana Cancer Centers

Indianapolis, Indiana, United States

Investigative Clinical Research of Indiana, LLC

Indianapolis, Indiana, United States

Clarian Arnett Cancer Center

Lafayette, Indiana, United States

Medical Consultants, PC

Muncie, Indiana, United States

Cancer Care Center

New Albany, Indiana, United States

Memorial Hospital of South Bend

South Bend, Indiana, United States

Hope Center

Terre Haute, Indiana, United States

McFarland Clinic, P.C.

Ames, Iowa, United States

Heartland Hematology-Oncology Associates, Inc.

Council Bluffs, Iowa, United States

Siouxland Hematology/Oncology Assoc., LLP

Sioux City, Iowa, United States

Kansas City Cancer Centers - Southwest

Overland Park, Kansas, United States

Cancer Center of Kansas

Wichita, Kansas, United States

Commonwealth Cancer Center

Danville, Kentucky, United States

Kentucky Cancer Clinic

Hazard, Kentucky, United States

Western Kentucky Hematology and Oncology Group

Paducah, Kentucky, United States

Christus St. Francis Cabrini Cancer Center

Alexandria, Louisiana, United States

Hematology-Oncology Clinic

Baton Rouge, Louisiana, United States

Annapolis Oncology Center

Annapolis, Maryland, United States

Greater Baltimore Medical Center

Baltimore, Maryland, United States

St. Agnes Health Care

Baltimore, Maryland, United States

Auerbach Hematology Oncology Associates

Baltimore, Maryland, United States

Maryland Hematology Oncology Association

Baltimore, Maryland, United States

Center for Cancer and Blood Disorders

Bethesda, Maryland, United States

Oncology-Hematology Associates, P.A.

Clinton, Maryland, United States

Maryland Oncology Hematology, PA

Columbia, Maryland, United States

Carroll County Cancer Center

Westminster, Maryland, United States

Boston Medical Center

Boston, Massachusetts, United States

Fallon Clinic at Worcester Medical Center

Worcester, Massachusetts, United States

Henry Ford Health System

Detroit, Michigan, United States

Cancer & Hematology Centers of Western Michigan

Grand Rapids, Michigan, United States

Kalamazoo Hematology and Oncology

Kalamazoo, Michigan, United States

Hematology Oncology Associates of Ohio & Michigan, PC

Lambertville, Michigan, United States

Breslin Cancer Center / Great Lakes Cancer Institute

Lansing, Michigan, United States

Oncology Care Associates, P.L.L.C.

Saint Joseph, Michigan, United States

Providence Cancer Center

Southfield, Michigan, United States

Osteopathic Medical Hematology & Oncology

Woodhaven, Michigan, United States

St. Luke's Hospital

Duluth, Minnesota, United States

Metro MN CCOP

Minneapolis, Minnesota, United States

Hubert H. Humphrey Cancer Center

Robbinsdale, Minnesota, United States

St. Louis Cancer Center

Chesterfield, Missouri, United States

Capital Region Medical Center/Cancer Center

Jefferson City, Missouri, United States

Heartland Hematology-Oncology Associates, Inc.

Kansas City, Missouri, United States

Kansas City Veterans Administration Medical Center

Kansas City, Missouri, United States

St. Joseph Oncology

Saint Joseph, Missouri, United States

Great Falls Clinic, LLP

Great Falls, Montana, United States

Great Plains Regional Medical Center

North Platte, Nebraska, United States

Creighton Cancer Center

Omaha, Nebraska, United States

Las Vegas Cancer Center

Henderson, Nevada, United States

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States

Veterans Affairs New Jersey Healthcare System

East Orange, New Jersey, United States

Drs. Forte, Schleider, Attas and Condemi, PA

Englewood, New Jersey, United States

St. Barnabas Medical Center

Livingston, New Jersey, United States

Newark Beth Israel Hospital

Newark, New Jersey, United States

Somerset Hematology Oncology Associates

Somerville, New Jersey, United States

Sparta Cancer Center

Sparta, New Jersey, United States

New Mexico Cancer Care Associates

Santa Fe, New Mexico, United States

Stratton VA Medical Center IRB

Albany, New York, United States

Buffalo Institute for Medical Research, Inc.

Buffalo, New York, United States

Erie County Medical Center

Buffalo, New York, United States

Goshen Medical Associates

Goshen, New York, United States

Huntington Medical Group

Huntington Station, New York, United States

North Shore-Long Island Jewish Health System

Lake Success, New York, United States

Arena Oncology Associates

New Hyde Park, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

New York Presbyterian Hospital-Cornell Campus

New York, New York, United States

Interlakes Foundation, Inc.

Rochester, New York, United States

Richmond University Medical Center

Staten Island, New York, United States

SUNY Upstate Medical University

Syracuse, New York, United States

Eastchester Center for Cancer Care

The Bronx, New York, United States

New York Medical College

Valhalla, New York, United States

Cancer Care of WNC

Asheville, North Carolina, United States

Alamance Regional Medical Center

Burlington, North Carolina, United States

Blood and Cancer Clinic

Fayetteville, North Carolina, United States

Gaston Hematology & Oncology

Gastonia, North Carolina, United States

Carolina Oncology Specialist, PA

Hickory, North Carolina, United States

Emerywood Hematology/Oncology

High Point, North Carolina, United States

Raleigh Hematology Oncology / Associates, P.C.

Raleigh, North Carolina, United States

Hanover Medical Specialists, P.A.

Wilmington, North Carolina, United States

St. Alexius Clinical Research Services

Bismarck, North Dakota, United States

Gabrail Cancer Center

Canton, Ohio, United States

Oncology Hematology Care, Inc.

Cincinnati, Ohio, United States

Oncology Partners Network

Cincinnati, Ohio, United States

University Hospitals of Cleveland

Cleveland, Ohio, United States

Hematology Oncology Consultants Inc.

Columbus, Ohio, United States

Dayton Clinical Oncology Program

Dayton, Ohio, United States

Dayton Oncology & Hematology

Kettering, Ohio, United States

Toledo Community Hospital Oncology Program

Toledo, Ohio, United States

Trilogy Cancer Center

Wooster, Ohio, United States

Cancer Care Associates

Oklahoma City, Oklahoma, United States

Oklahoma Oncology and Hematology

Tulsa, Oklahoma, United States

Willamette Valley Cancer Center

Eugene, Oregon, United States

Onc-Hem of Lehigh Valley, PC

Bethlehem, Pennsylvania, United States

Hematology & Oncology Associates of NEPA

Dunmore, Pennsylvania, United States

Medical Oncology Associates

Kingston, Pennsylvania, United States

Regional Hematology Oncology Associates

Langhorne, Pennsylvania, United States

Greater Philadelphia Cancer and Hematology Specialists, PC

Philadelphia, Pennsylvania, United States

UPMC Cancer Pavillioin

Pittsburgh, Pennsylvania, United States

Guthrie Research Institute

Sayre, Pennsylvania, United States

Scranton Hematology Oncology

Scranton, Pennsylvania, United States

Roger Williams Medical Center

Providence, Rhode Island, United States

MUSC Hollings Cancer Center

Charleston, South Carolina, United States

Cancer Center of the Carolinas

Greenville, South Carolina, United States

Low Country Hematology & Oncology

Mt. Pleasant, South Carolina, United States

Santee Hematology/Oncology

Sumter, South Carolina, United States

Avera Research Institute

Sioux Falls, South Dakota, United States

Chattanooga Oncology Hematology Associates

Chattanooga, Tennessee, United States

The Family Cancer Center, PLLC

Collierville, Tennessee, United States

The Cancer Center of Cookeville Regional Medical Center

Cookeville, Tennessee, United States

The Jones Clinic

Germantown, Tennessee, United States

East Tennessee Oncology/Hematology

Knoxville, Tennessee, United States

University of Tennesee Medical Center

Knoxville, Tennessee, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Texas Cancer Center

Abilene, Texas, United States

Texas Oncology, P.A.

Arlington, Texas, United States

Southwest Regional Cancer Center

Austin, Texas, United States

Texas Oncology, PA

Austin, Texas, United States

Texas Oncology, PA

Beaumont, Texas, United States

Texas Oncology, P.A.

Bedford, Texas, United States

Coastal Bend Cancer Center

Corpus Christi, Texas, United States

South Texas Institute of Cancer and Blood Disorders

Corpus Christi, Texas, United States

Texas Oncology

Dallas, Texas, United States

Dallas Oncology Consultants

Dallas, Texas, United States

Texas Oncology, PA / Methodist Charlton Cancer Center

Dallas, Texas, United States

Texas Oncology PA

Dallas, Texas, United States

Texas Cancer Center

Denton, Texas, United States

El Paso Cancer Treatment Center

El Paso, Texas, United States

Texas Cancer Center

Fort Worth, Texas, United States

Texas Oncology, PA

Garland, Texas, United States

Lee C. Drinkard, MD

Grapevine, Texas, United States

Houston Cancer Institute

Houston, Texas, United States

Medicus Alliance Clinical Research Organization, LLC

Houston, Texas, United States

Lake Vista Cancer Center

Lewisville, Texas, United States

Longview Cancer Center

Longview, Texas, United States

Texas Cancer Center of Mesquite

Mesquite, Texas, United States

Texas Oncology, P.A.

Midland, Texas, United States

Texas Oncology - Odessa

Odessa, Texas, United States

Paris Regional Cancer Center

Paris, Texas, United States

Cancer Care Network of South Texas

San Antonio, Texas, United States

Cancer Care Center of South Texas

San Antonio, Texas, United States

CTRC Institute for Drug Development

San Antonio, Texas, United States

Texas Cancer Center - Sherman

Sherman, Texas, United States

Blood and Cancer Center of East Texas

Tyler, Texas, United States

Tyler Hematology/Oncology, PA

Tyler, Texas, United States

Texas Oncology, PA

Tyler, Texas, United States

Texas Oncology

Waco, Texas, United States

Northern Utah Associates

Ogden, Utah, United States

Utah Cancer Specialists

Salt Lake City, Utah, United States

The University of Vermont

Burlington, Vermont, United States

White River Junction VAMC

White River Junction, Vermont, United States

Cancer Specialists of Tidewater

Chesapeake, Virginia, United States

Fairfax/Northern Virginia Hematology/Oncology

Fairfax, Virginia, United States

Lynchburg Hematology Oncology Clinic, Inc.

Lynchburg, Virginia, United States

Peninsula Cancer Institute Riverside Cancer Center

Newport News, Virginia, United States

Virginia Oncology Associates

Norfolk, Virginia, United States

Virginia Cancer Institute

Richmond, Virginia, United States

Oncology and Hematology Associates of Southwest Virginia, Inc.

Salem, Virginia, United States

Masoom Kandahari, MD, PC

Woodbridge, Virginia, United States

Puget Sound Cancer Center - Edmonds

Edmonds, Washington, United States

Providence Everett Medical Center

Everett, Washington, United States

Puget Sound Cancer Center, Inc

Seattle, Washington, United States

Cancer Care Northwest, US Oncology

Spokane, Washington, United States

Northwest Medical Specialties, PLLC

Tacoma, Washington, United States

Wenatchee Valley Medical Center

Wenatchee, Washington, United States

Yakima Valley Memorial Hospital / North Star Lodge

Yakima, Washington, United States

Gundersen Clinic, Ltd.

La Crosse, Wisconsin, United States

Alyce & Elmore Kraemer Cancer Center

West Bend, Wisconsin, United States

Hospital Auxillo Mutuo, Auxilio Mutuo Cancer Center

San Juan, , Puerto Rico

Countries

United States; Puerto Rico

References

Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. J Clin Oncol. 2015 Nov 20;33(33):3921-9. doi: 10.1200/JCO.2014.58.7618. Epub 2015 Jun 8.

Reference Type: DERIVED

PMID: 26056177 (View on PubMed)

Other Identifiers

C05009

Identifier Type: -

Identifier Source: org_study_id